Categories: CancerNews

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating at the upcoming H.C. Wainwright’s 24th Annual Global Investment Conference taking place on September 12-14, 2022. Details for the event are as follows:

H.C. Wainwright 24th Annual Global Investment Conference
Date:   September 12-14, 2022
Webcast:   Click HERE

Management will be available for virtual 1×1 meetings with investors. Please contact your H.C. Wainwright representative to request a meeting.

A replay of the webcast presentation will be available in the Investor section of Galecto’s website at https://ir.galecto.com/news-and-events/events.

About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Galecto, Inc.  
Hans Schambye, CEO  
Jon Freve, CFO  
+45 70 70 52 10  
   
Investors/US Media/EU
Ashley R. Robinson Sandya von der Weid
arr@lifesciadvisors.com svonderweid@lifesciadvisors.com
+1 617 430 7577 +41 78 680 0538

Staff

Recent Posts

Hankyung.com introduces: MecKare, Leading the AI-powered Innovation in Health Monitoring Solution

- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov.…

4 hours ago

Redefining the Standard of Care: Introducing the Aulisa® Monitor Camera for Advanced Patient Monitoring

PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…

16 hours ago

Defence Announces Closing of Securities for Debenture Financing

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…

21 hours ago

NuGen Announces Canada-Wide Launch of InsuJet

3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…

22 hours ago